Cargando…

A systematic review of CXCL13 as a biomarker of disease and treatment response in rheumatoid arthritis

BACKGROUND: The B cell chemoattractant CXCL13 is a promising biomarker in rheumatoid arthritis (RA), with a plausible role in supporting diagnosis, monitoring disease activity and as a prognostic value. It is a key chemokine driving the formation of lymphoid follicles within the inflamed synovium. T...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bechman, Katie, Dalrymple, Anthony, Southey-Bassols, Charles, Cope, Andrew P., Galloway, James B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7604968/ https://www.ncbi.nlm.nih.gov/pubmed/33292827 http://dx.doi.org/10.1186/s41927-020-00154-3

Ejemplares similares

Is background methotrexate advantageous in extending TNF inhibitor drug survival in elderly patients with rheumatoid arthritis? An analysis of the British Society for Rheumatology Biologics Register
por: Bechman, Katie, et al.
Publicado: (2020)

A systematic review and network meta-analysis of the safety of early interventional treatments in rheumatoid arthritis
por: Adas, Maryam A, et al.
Publicado: (2021)

Corrigendum to: Is background methotrexate advantageous in extending TNF inhibitor drug survival in elderly patients with rheumatoid arthritis? An analysis of the British Society for Rheumatology Biologics Register
por: Bechman, Katie, et al.
Publicado: (2020)

Mental health, fatigue and function are associated with increased risk of disease flare following TNF inhibitor tapering in patients with rheumatoid arthritis: an exploratory analysis of data from the Optimizing TNF Tapering in RA (OPTTIRA) trial
por: Bechman, Katie, et al.
Publicado: (2018)

A Systematic Review and Meta-Analysis of Anti-Rheumatic Drugs and Pneumococcal Vaccine Immunogenicity in Inflammatory Arthritis
por: Nagra, Deepak, et al.
Publicado: (2023)

Real-world evidence for prehospital COVID-19 treatment in systemic autoimmune rheumatic disease
por: Bechman, Katie, et al.
Publicado: (2023)

T cells in rheumatoid arthritis
por: Cope, Andrew P
Publicado: (2008)

Baseline CXCL10 and CXCL13 levels are predictive biomarkers for tumor necrosis factor inhibitor therapy in patients with moderate to severe rheumatoid arthritis: a pilot, prospective study
por: Han, Bobby Kwanghoon, et al.
Publicado: (2016)

CXCL13, CXCL10 and CXCL8 as Potential Biomarkers for the Diagnosis of Neurosyphilis Patients
por: Wang, Cuini, et al.
Publicado: (2016)

CXCL13 predicts disease activity in early rheumatoid arthritis and could be an indicator of the therapeutic ‘window of opportunity’
por: Greisen, Stinne Ravn, et al.
Publicado: (2014)

The new entries in the therapeutic armamentarium: The small molecule JAK inhibitors
por: Bechman, Katie, et al.
Publicado: (2019)

Corrigendum to “The new entries in the therapeutic armamentarium: The small molecule JAK inhibitors” [Pharmacol. Res. 147 (2019) 104392]
por: Bechman, Katie, et al.
Publicado: (2020)

Expression of chemokines CXCL4 and CXCL7 by synovial macrophages defines an early stage of rheumatoid arthritis
por: Yeo, L, et al.
Publicado: (2016)

Infection profile of immune-modulatory drugs used in autoimmune diseases: analysis of summary of product characteristic data
por: Dey, Mrinalini, et al.
Publicado: (2022)

CXCL13/CXCR5 axis facilitates endothelial progenitor cell homing and angiogenesis during rheumatoid arthritis progression
por: Tsai, Chun-Hao, et al.
Publicado: (2021)

Targeting B cells for the treatment of rheumatoid arthritis
por: Oligino, Thomas J, et al.
Publicado: (2003)

Meningococcal arthritis and myopericarditis: a case report
por: Steele, Lloyd, et al.
Publicado: (2017)

Remote Measurement in Rheumatoid Arthritis: Qualitative Analysis of Patient Perspectives
por: White, Katie M, et al.
Publicado: (2021)

The immunosuppressed traveler: infection risks with autoimmunity and immunosuppression, vaccinations, and general travel advice
por: Allen, Victoria, et al.
Publicado: (2020)

Intrathecally produced CXCL13: A predictive biomarker in multiple sclerosis
por: DiSano, Krista D, et al.
Publicado: (2020)

Redox-Mediated Mechanisms Fuel Monocyte Responses to CXCL12/HMGB1 in Active Rheumatoid Arthritis
por: Cecchinato, Valentina, et al.
Publicado: (2018)

Diagnostic delay is common for patients with axial spondyloarthritis: results from the National Early Inflammatory Arthritis Audit
por: Russell, Mark D, et al.
Publicado: (2021)

Biomarkers for Treatment Response in Rheumatoid Arthritis: Where are they?
por: Zhao, Sizheng Steven, et al.
Publicado: (2020)

The safety of JAK-1 inhibitors
por: Clarke, Benjamin, et al.
Publicado: (2021)

Biomarkers in Rheumatoid Arthritis
por: Goëb, Vincent, et al.
Publicado: (2014)

Biomarkers in Rheumatoid Arthritis
por: Shapiro, Samantha C
Publicado: (2021)

Corrigendum to: Diagnostic delay is common for patients with axial spondyloarthritis: results from the National Early Inflammatory Arthritis Audit
por: Russell, Mark D, et al.
Publicado: (2021)

Differential Methylation as a Biomarker of Response to Etanercept in Patients With Rheumatoid Arthritis
por: Plant, Darren, et al.
Publicado: (2016)

The CXCL13 Index as a Predictive Biomarker for Activity in Clinically Isolated Syndrome
por: Pike, Steven C., et al.
Publicado: (2023)

The Efficacy of Moxibustion on the Serum Levels of CXCL1 and β-EP in Patients with Rheumatoid Arthritis
por: Tao, Siyu, et al.
Publicado: (2021)

Humoral Response to Microbial Biomarkers in Rheumatoid Arthritis Patients
por: Jasemi, Seyedesomaye, et al.
Publicado: (2021)

Circulating Biomarkers for Predicting Infliximab Response in Rheumatoid Arthritis: A Systematic Bioinformatics Analysis
por: Huang, Qiu-lan, et al.
Publicado: (2017)

Cytokines as Biomarkers in Rheumatoid Arthritis
por: Burska, Agata, et al.
Publicado: (2014)

CXCL13 is a predictive biomarker in idiopathic multicentric Castleman disease
por: Pierson, Sheila K., et al.
Publicado: (2022)

CXCL10 as a shared specific marker in rheumatoid arthritis and inflammatory bowel disease and a clue involved in the mechanism of intestinal flora in rheumatoid arthritis
por: Guan, Yin, et al.
Publicado: (2023)

microRNA-23 inhibits inflammation to alleviate rheumatoid arthritis via regulating CXCL12
por: Gao, Bo, et al.
Publicado: (2021)

Assessment of Adipokines, CXCL16 Chemokine Levels in Patients With Rheumatoid Arthritis Combined With Metabolic Syndrome
por: Turgunova, Lyudmila Gennadyevna, et al.
Publicado: (2021)

BCA-1 (CXCL13) and SLC (CCL21) production and lymphoid neogenesis in rheumatoid synovitis
por: Manzo, A, et al.
Publicado: (2003)

A Systematic Review of Serum Biomarkers Anti-Cyclic Citrullinated Peptide and Rheumatoid Factor as Tests for Rheumatoid Arthritis
por: Taylor, Peter, et al.
Publicado: (2011)

Regulatory T cells as a biomarker for response to adalimumab in rheumatoid arthritis
por: Nguyen, Dao X., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_4aae49b569qp2q7k82i7nninci